Frequency and clinical implications of lupus anticoagulant in patients with terminal chronic renal failure in hemodialysis;Frecuencia e implicaciones clínicas del anticoagulante lúpico en pacientes con insuficiencia renal crónica estadio V en programa de hemodiálisis en Maracaibo, Venezuela

Investigacion Clinica

Volumn 48, Issue 1, 2007, Pages 69-79

  Fernández Abreu, Mary C ^a   Diez Ewald, María ^b   Briceño, Soledad ^a   Torres Guerra, Enrique ^b   Rodríguez, Zulay ^b   Fernández, Nelson ^b  

^a Hospital General del Sur   (Venezuela)

^b UNIVERSIDAD DEL ZULIA   (Venezuela)

Author keywords

Anti phospholipid antibodies; Chronic renal failure; Hemodialysis; Lupus anticoagulant; Trombosis

Indexed keywords

LUPUS ANTICOAGULANT;

ADULT; AGED; ARTICLE; CATHETERIZATION; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; SCREENING; TERMINAL DISEASE; THROMBOSIS; VASCULAR ACCESS;

ADOLESCENT; ADULT; AGED; ARTERIOVENOUS SHUNT, SURGICAL; CASE-CONTROL STUDIES; CATHETERIZATION; CATHETERS, INDWELLING; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; INCIDENCE; INFECTION; KIDNEY FAILURE, CHRONIC; LUPUS COAGULATION INHIBITOR; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; RENAL DIALYSIS; THROMBOPHILIA; THROMBOSIS; VENEZUELA;

EID: 34248180505     PISSN: 05355133     EISSN: 05355133     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Detarsio G, Ordi-Ros J. Anticoagulante Lúpico. Rev. Ibe roa mer. Tromb. Hemostasia 1997; 10 (S1):98-102.
2. Diez-Ewald M. Anticuerpos antifosfolípidos. Revisión. Invest Clin 1993; 34:143-158.
3. Triplett DA. Antiphospholipid antibodies and thrombosis. Arch Pathol Lab Med 1993; 117:78-88.
4. Triplett DA. Lupus anticoagulants: misnomer, paradox, riddle, epiphenomenona. Hematol Pathol 1988; 2:121-143.
5. Reverter-Calatatud JC. Mecanismos trombóticos de los anticuerpos antifosfolípido. Rev Iberoamer Tromb Hemostasia 1997; 10(S1):105-109.
6. Mueller JF, Ratnoff O, Heinle RW. Observations on the characteristics of an unusual circulanting anticoagulant. J Lab Clin Med 1951; 38:254-261.
7. Conley CL, Hartman RC. Hemorrhagic disorders caused by circulanting anticoagulants in patients with disseminated lupus erythematosus. J Clin Invest 1952; 150:621-622.
8. Bowie EJW, Thompson JH, Pescuzzi CA, Owen CA. Thrombosis in systemic lupus erythematosus de spite circulanting anticoagulants. J Lab Clin Med 1963; 62:416-430.
9. Veltkamp JJ, Kerkhoven P, Loelinger EA. Circulating anticoagulant in disseminated lupus erythematosus: proposed mode of action. Haemostasis 1974; 2:253-259.
10. Harris EN, Gharavi AE, Hughes GRV. Anti-phospholipid antibodies. Clin Rheum Dis 1985; 11:591-609.
11. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346; 752-763.
12. Petri M. Pathogenesis and treatment of the antiphospholipid antibody syndrome. Med Clin N Am 1997; 81:151-167.
13. Galli M. ACA directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335; 1544-1547.
14. Wagenknecht DR, McIntyre JA. Changes in β2GPI antigenicity induced by phospholipid binding. Thromb Haemost 1993; 69:361-365.
15. Matsuura E, Igarashi Y, Fujimoto M. Anticardiolipin cofactor(s) and differential diagnosis of autoinmune disease. Lancet 1990; ii:177-178.
16. McNiel HP, Simpson RJ, Chesterman CL, Krilis SA. Antiphospholipid antibodies are direct against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87:4120-4124.
17. Oosting JD, Derksen RHWM, Entjes HTI, Bouma BN, Groot PG. Lupus anticoagulant activityis frecuently dependent on the presence of β2-glycoprotein I. Thromb Haemost 1992; 67:499-502.
18. Ordi-Ros J. Anticuerpos antifosfolípido y el cofactor. Biol Clin Hematol 1991; 13: 69-70.
19. Vermylen J, Arnout J. Is the antiphospholipid syndrome caused by antibodies direct against physiologically relevant phospholipid-protein complexes? J Lab Clin Med 1992; 120: 10-12.
20. Bevers EM, Galli M, Barbui T. Lupus anticoagulant IgǴs (LA) are not directed to phospholipids only but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991; 66:629-632.
21. Brunet P, Aillaud MF, San Marco M, Philip-Joet C, Dussol B, Ber nard D, Juhan-Vague I, Berland Y. Antiphospholipids in hemodialysis patients: Relationship between lupus anticoagulant and thrombosis. Kidney Int 1995, 48:794-800.
22. Chew SL, Lins RL, Daelemans R, Zachee P, De Clerck LS, Vermylen J. Are antiphospholipid antibodies clinically relevant in dialysis patients? Nephrol Dial Transplant 1992; 7:1194-1198.
23. Fabrizi F, Sangiorgio R, Pontoriero G, Corti M, Tentori F, Troina E, Locatelli F. Antiphospholipid (aPL) antibodies in end-stage renal disease. J Nephrol 1999; 12:89-94.
24. García-Martin F, De Arriba G, Carrascosa T, Moldenhauer F, Martin-Escobar E, Val J, Saiz F. Anticardiolipin antibodies and lupus anticoagulant in end-stage renal diasease. Nephrol Dial Transplant 1991; 6:543-547.
25. Joseph RE, Radhakrishnan J, Appel GB. Antiphospholipid antybody syndrome and renal disease. Curr Opin Nephrol Hypertens 2001; 10:175-181.
26. Nampoory MR, Das KC, Johny KV, Al-Hilali N, Abraham M, Easow S, Saed T, Al-Muzeirei IA, Sugathan TN, Al-Mousawi M. Hypercoagulability, a serious problem in patients with ESRD on maintenance hemodialysis, and its corrections after kidney transplantation. Am J Kidney Dis 2003; 42:797-805.
27. Quereda C, Pardo A, La mas S, Marcen R, García-Avello A, Orofino L, Navarro JL, Ortuño J. High prevalence of lupus anticoagulant in hemodialysis patients. Life Support Sist 1985; 3(S1):58-62.
28. Quereda C, Pardo A, La mas S, Orofino L, García-Avello A, Marcen R, Teruel JL, Ortuño J. Lupus-like in vitro anticoagulant activity in end-stage renal disease. Nephron 1988; 49:39-44.
29. Joseph RE, Radhakrishnan J, Ap pel GB. Relationship of anticardiolipin antibodies (ACLA) to oxidative stress in hemodialysis (HD) [Abstract]. J Am Soc Nephrol 1998; 9:254.
30. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Inter Med 1990; 112:682-698.
31. Thiagarajan P, Pengo V, Shapiro S. The use of the Dilute Russell Viper Venom Time for the diagnosis of lupus anticoagulants. Blood 1986; 68:869-874.
32. Phillips AO, Jones HW, Hambley H, Hillis AN, Hendry BM. Prevalence of lupus anticoagulant and anticardiolipin antibodies in haemodialysis patients. Nephron 1993; 65:350-353.
33. Joseph RE, Valeri A, Appel GB. Evidence for ongoing oxidative stress in hemodialysis patients [Abstract]. J Am Soc Nephrol 1998; 9:254A.
34. Prakash R, Miller CC, Suki WN. Anticardiolipin antybody in patients on maintance hemodialysis and its association with recurrent AV graft thrombosis. Am J Kidney Dis 1995; 26: 347-235.
35. Roubey RAS. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other antiphospholipis autoantibodies. Blood 1994; 84:2854-2867.
36. Brey RL, Coull BM. Antiphospholipid antibodies: origin, specifity, and mechanism of action. Stroke 1992; 23(suppl 1):I-15-I-18.00.
37. Jamshid R, Reza SA, Abbas G, Raha A. Incidente of arteriovenous trombosis and the role of anticardiolipin antibodies in hemodiálisis patients. Int Urol Nephrol 2003; 35:275-282.
38. McNiel HP, Chesterman CL, Krilis SA. Immunology and clinical importance on antiphospholipid antibodies. Adv Inmunol 1991; 49:193-280.
39. Diskin CJ, Stokes TJ, Pennell AT. Pharmacologic intervention to prevent hemodialysis vascular access thrombosis. Nephron. 1993; 64: 1-26.
40. Page B, Zingraff J, Bourquelot P. Clotting of vascular access in dialysis patients associated to anticardiolipin antibodies. Kidney Int 1992; 42. 223.
41. Sitter T, Spannagl M, Schiffl H. Anticardiolipin antibodies and lupus anticoagulant in patients treated with different methods of renal replacement therapy in comparison to patients with systemic lupus erythematosus. Ann Hematol 1992; 65:79-82.
42. Magy N, Gil H, Racadot E, Dupond JL. Relative value of different antiphospholipid antibodies detected in a department of internal medicine: retrospective study of 124 patients. Rev Med Interne 2002; 23:696-702.
43. Gargiulo P, Goldberg J, Romani B, Schiaffini R, Ciampalini P, Faulk W, McIntyre JA. Qualitative and quantitative studies of antibodies to phospholipids in diabetes mellitus. Clin Exp Immunol 1999; 118:30-34.
44. Gin H, Vergnot V, Diakou V, Perret AM, Poix J, Cassagne C, Maneta-Peyret L. Anti-phospholipid antibodies in diabetes mellitus. Clin. Chem Lab Med 2002; 40:604-608.
45. Valeri A, Jo seph R, Radhakrishnan J. A large prospective survey of anti-cardiolipin antibodies in chronic hemodialysis patients. Clin Nephrol 1999; 51:116-121.